The Role of RECIST 1.1 criteria in Evaluating Response of Locally Advanced Rectal Cancer to Neoadjuvant Therapy using Multiparametric MRI

Abstract

Background: This study elucidates the pivotal role of using RECIST 1.1 criteria in the MRI evaluation of tumor response among patients with rectal cancer undergoing neoadjuvant therapy. By employing a systematic, reproducible approach to assessing therapeutic outcomes, RECIST 1.1 has become a cornerstone of evidence-based oncologic practice. Leveraging advanced imaging modalities such as multi-parametric MRI, RECIST 1.1 enables precise tumor measurement, response classification, and correlation with pathological outcomes. The findings underscore its indispensability in facilitating precision oncology, enhancing treatment planning, and optimizing patient-specific strategies.